trending Market Intelligence /marketintelligence/en/news-insights/trending/r1WEdUtGOrNtrAWna3Mz0g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Yunnan Hongxiang Q4 profit falls YOY

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

What’s next in Cloud?

Blog

Global M&A Infographic Q1 2021

Blog

COVID-19 Impact & Recovery: Private Equity


Yunnan Hongxiang Q4 profit falls YOY

4914208 said its fourth-quarter normalized net income was 6 fen per share, a decline from 6 fen per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 32.7 million yuan, a decline from 33.2 million yuan in the prior-year period.

The normalized profit margin fell to 2.1% from 2.8% in the year-earlier period.

Total revenue climbed 20.1% on an annual basis to 1.44 billion yuan from 1.19 billion yuan, and total operating expenses rose 20.9% year over year to 1.38 billion yuan from 1.14 billion yuan.

Reported net income grew 32.2% from the prior-year period to 95.1 million yuan, or 18 fen per share, from 71.9 million yuan, or 14 fen per share.

For the year, the company's normalized net income totaled 46 fen per share, compared with the S&P Capital IQ consensus normalized EPS estimate of 77 fen.

EPS declined from 48 fen in the prior year.

Normalized net income was 236.9 million yuan, a gain of 8.9% from 217.5 million yuan in the prior year.

Full-year total revenue rose 20.2% from the prior-year period to 5.32 billion yuan from 4.43 billion yuan, and total operating expenses rose 21.0% year over year to 4.94 billion yuan from 4.08 billion yuan.

The company said reported net income increased 16.5% year over year to 346.4 million yuan, or 67 fen per share, in the full year, from 297.3 million yuan, or 65 fen per share.

s of Feb. 26, US$1 was equivalent to 6.54 yuan.Yunnan Hongxiang Yixintang Pharmaceutical Co. Ltd.

4914208 said its fourth-quarter normalized net income was 6 fen per share, a decline from 6 fen per share in the prior-year period.